【瞩目】新华制药重磅1类新药出击,1300亿市场再掀巨浪

米内网
Sep 24

精彩内容近日,CDE官网数据显示,新华制药的1类新药LXH-1211片获批临床,适应症为肺动脉高压,有望为公司加码抢攻1300亿心脑血管系统药物市场。今年5月,公司的1类新药OAB-14干混悬剂启动了II期临床,新华制药的创新成果逐步落地,未来可期。图1:新华制药最新获批临床的新药来源:CDE官网资料显示,LXH-1211片是一款抗肺动脉高压1类新药,新华制药在2020年与中南大学签订的了《...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10